Drug Information Association Logo

Planning and Implementing Large Cardiovascular Outcomes Studies: Opportunities & Challenges

| Online

« Back to Listing




This Solution Provider Archive Webinar is brought to you by DIA in cooperation with Cytel.


International regulators are calling sponsors to increasingly conduct CV outcomes studies. The costs necessitated by the additional trials will be measured in the $100’s of millions of dollars per program.  The full impact to be felt by every sponsor, of any size engaged in therapeutic areas where cardio-related events are a concern.

Add Increased Complexity to Increased Costs

Implementation and support complexity levels typically go up across the board, beginning with effectively managing the hurdles of combining data from multiple studies and then supporting the need for thoroughly integrated analysis and reports.

The greatest costs and resource strains will apply to (naturally) the biggest, most important trials - CV outcome trials (CVOT).  Assessing necessity, design, and timing of CVOT trials is of critical strategic importance. 

With some sponsors the experienced resources exist but they’re already stretched across multiple programs.  Other developers don’t have the capabilities, resources and tools in the first place.

Background Info: Relevant FDA Guidance

Diabetes trials in particular heavily employ cardiovascular outcomes studies.  Click here for a link to relevant FDA Guidances.

Relevant FDA Guidance: Evaluating  Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Featured Topics 

  • Designing non-inferiority trials for CV outcome studies
  • Including adaptations: sample size re-estimation, population enrichment, superiority switch
  • Event modeling, interim analysis and study end forecasting, interim simulations, predicitive interval plots
  • Describe strategies to address pre and post-marketing requirements

Special Offers 

Registration for a Solution Provider Archive Webinar is FREE! Sign up by using the Register Online button.

Contact Information 

Registration Questions
Toll Free 1.888.257.6457
Phone +1.215.442.6100
Fax +1.215.442.6199
Monday-Friday 8:30AM-8:00PM ET

Archived Webinar Details
Carolyn Callahan
DIA North America
Phone +1.215.442.6194
Fax +1.215.442.6199

Technical Requirements 

Click here for minimum system requirements.


Previous Next


Day 1 Tuesday, Oct 22, 2013

  • 11:00AM - 11:59PM

    Planning and Implementing Large Cardiovascular Outcomes Studies: Opportunities & Challenges


    • Planning and Implementing Large Cardiovascular Trials - Paul Strumph and Zoran Antonijevic
      Paul Strumph, MD
      Vice President, Clinical Development
      Lexicon Pharmaceuticals, United States
    • Zoran Antonijevic, MSc
      Senior Director, Strategic Consulting
      Cytel, Inc., United States

Registration Fees 

Other Fees

Register Online

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

« Back to Listing Back To Top